Monday 21 March 2016

Do investors in new Mellon venture SalvaRX know of RSH row?

A fascinating story in the Financial Times tells how Jim Mellon is bringing a cancer drug biotech company to the Alternative Investment Market this week Jim Mellon-backed biotech to join AIM. As it is operating in a market potentially worth billions of dollars, SalvaRX may well attract enthusiastic interest from investors.
However, the article does not mention anything about Rivington Street Holdings, Tom Winnifrith or the investigation into allegations of fraud. Nor, therefore, does it question whether Mellon knew about the allegations or indeed about the investigation by KPMG, which the RSH board - of which he was chairman - had commissioned at great expense (Mellon has tested credulity by indicating on Twitter that he knew nothing about it). Nor does it ask if Mellon responded to KPMG's findings by dismissing Winnifrith.
Are these not questions which potential investors in other Mellon ventures would want asking - not to mention answering?

No comments:

Post a Comment